Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00151294 · ClinicalTrials.gov registry record · Phase 4
The Efficacy and Safety of Escitalopram for Depression in Multiple Sclerosis
A Phase 4 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT00151294 is a Phase 4 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 20 participants.
The verdict
NCT00151294, a Phase 4 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
Emotionally labile, depressed participants with multiple sclerosis treated with escitalopram will have a greater reduction in emotional lability scores and in their psychological distress scores than those who are randomized to receive placebo.
Interventions
- DRUG escitalopram oxalate antidepressant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2004-11 |
| Est. Completion | 2006-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00151294
The ClinicalTrials.gov registry entry for NCT00151294 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which escitalopram oxalate antidepressant is the first listed.
NCT00151294 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00151294 about?
NCT00151294 is a clinical study titled "The Efficacy and Safety of Escitalopram for Depression in Multiple Sclerosis". Emotionally labile, depressed participants with multiple sclerosis treated with escitalopram will have a greater reduction in emotional lability scores and in their psychological distress scores than those who are randomized to receive placebo.
What is the current status of trial NCT00151294?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2004-11. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00151294?
The interventions under investigation include: escitalopram oxalate antidepressant (DRUG).
Who is sponsoring clinical trial NCT00151294?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.